modelEtidronicAcid
Extends from Pharmacolibrary.Drugs.ATC.M.M05BA01.
Information
| name: | EtidronicAcid | |
| ATC code: | M05BA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 0.7 | L |
| clearance: | 0.06 | L/kg/h |
| other parameters in model implementation | ||
Etidronic acid is a bisphosphonate drug that inhibits bone resorption, commonly used for the treatment of osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy. It was one of the first bisphosphonates developed and is now less commonly used, having been largely replaced by newer bisphosphonates.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult subjects based on available pharmacological profiles and regulatory documents. No direct PK model or clinical PK parameterization with numerical values published in peer-reviewed literature.
References
Mitchell, DY, et al., & Powell, JH (2000). Effect of renal function on risedronate pharmacokinetics after a single oral dose. British journal of clinical pharmacology 49(3) 215–222. DOI:10.1046/j.1365-2125.2000.00135.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/10718776
Ogura, Y, et al., & Orimo, H (2004). Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. Journal of bone and mineral metabolism 22(2) 111–119. DOI:10.1007/s00774-003-0458-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/14999521
Denk, E, et al., & Walczyk, T (2007). Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 22(10) 1518–1525. DOI:10.1359/jbmr.070617 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17576167
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)